Clinician’s Guide to Prevention and Treatment of Osteoporosis
Open accessThe DOI matches its Crossref record; 101 of the 102 references it cites were found in a registry or an index; 41 of the 169 sources its claims cite were checked for support.
Abstract
The Clinician's Guide to Prevention and Treatment of Osteoporosis was developed by an expert committee of the National Osteoporosis Foundation (NOF) in collaboration with a multispecialty council of medical experts in the field of bone health convened by NOF. Readers are urged to consult current prescribing information on any drug, device, or procedure discussed in this publication.
Overview
CoChat Summary
TL;DR
This NOF Clinician’s Guide provides recommendations for prevention, risk assessment, diagnosis, and treatment of osteoporosis in postmenopausal women and men age 50 and older, including BMD testing, vertebral imaging, FRAX-based intervention thresholds, and FDA-approved pharmacotherapy. It emphasizes that osteoporosis is common, underdiagnosed, and treatable, with treatment thresholds and drug-specific fracture risk reductions summarized.
Key findings
- Osteoporosis affects more than 9.9 million Americans, with an additional 43.1 million having low bone density; about 1 in 2 Caucasian women and approximately 1 in 5 men will experience an osteoporosis-related fracture. Annually, 2 million fractures are attributed to osteoporosis, causing more than 432,000 hospital admissions, almost 2.5 million medical office visits, and about 180,000 nursing home admissions; costs are expected to rise to $25.3 billion by 2025. Only 23% of women age 67 or older who have an osteoporosis-related fracture receive either a BMD test or a prescription for osteoporosis drug in the 6 months after fracture.
- Pharmacologic treatment is recommended for hip or vertebral fracture, T-score ≤−2.5 at the femoral neck, total hip, or lumbar spine, or low bone mass (T-score between −1.0 and −2.5) with a 10-year hip fracture probability ≥3% or a 10-year major osteoporosis-related fracture probability ≥20% by US-adapted FRAX.
- Universal recommendations include calcium intake of 1000 mg/day for men 50–70 and 1200 mg/day for women 51 and older and men 71 and older; vitamin D 800–1000 IU/day for adults age 50 and older; regular weight-bearing and muscle-strengthening exercise; fall risk assessment and modification; smoking cessation; and avoidance of excessive alcohol.
- Selected drug efficacy data: alendronate reduces spine and hip fractures by about 50% over 3 years; zoledronic acid reduces vertebral fractures by 70%, hip fractures by 41%, and nonvertebral fractures by 25% over 3 years; denosumab reduces vertebral fractures by about 68%, hip fractures by about 40%, and nonvertebral fractures by about 20% over 3 years; teriparatide reduces vertebral fractures by about 65% and nonvertebral fragility fractures by about 53%; raloxifene reduces vertebral fractures by about 30% with prior vertebral fracture and about 55% without; calcitonin reduces vertebral fracture occurrence by about 30% but has not been shown to reduce nonvertebral fractures; ibandronate reduces vertebral fractures by about 50% but nonvertebral fracture reduction has not been documented.
Methods
- Design: guideline developed by an expert committee of the National Osteoporosis Foundation in collaboration with a multispecialty council of medical experts in bone health; recommendations apply to postmenopausal women and men age 50 and older.
- Data or sample: no primary study sample; the Guide synthesizes evidence including NHANES III prevalence estimates, the Women’s Health Initiative, FDA prescribing information, WHO FRAX, and cost-effectiveness analyses.
- Main analysis: expert consensus and evidence synthesis; absolute risk thresholds for pharmacologic intervention were guided by a cost-effectiveness analysis; diagnostic assessment uses central DXA, vertebral imaging, and US-adapted WHO FRAX.
Limitations
- Stated: FRAX underestimates fracture risk in patients with recent fractures, multiple osteoporosis-related fractures, and increased fall risk; it has not been validated for lumbar spine BMD, is not intended for younger adults or children, and has not been validated in patients currently or previously treated with osteoporosis pharmacotherapy.
- Stated: evidence of efficacy beyond 5 years is limited; rare safety concerns such as osteonecrosis of the jaw and atypical femur fractures become more common beyond 5 years; there are relatively few data confirming fracture risk reductions with pharmacotherapy in patients selected by low bone mass plus FRAX thresholds; fracture data are limited in glucocorticoid-induced osteoporosis and in men; and in the absence of head-to-head trials, direct comparisons of risk reduction among drugs should be avoided.
- Evident: the text does not report a systematic search strategy or formal evidence-grading system; the therapeutic thresholds are described as clinical guidance only and “not rules,” requiring individualized clinical judgment.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures
![Fig. 1 Micrographs of normal vs. osteoporotic bone [9], from Dempster et al., with permission of The American Society for Bone and Mineral Research [9]](https://figures.cochat.ai/paper-figures/d609b75c87444980afa9b5aebc701061/clinicians-guide-to-prevention-and-treatment-of-osteoporosis-figure-1.jpg)
![Fig. 2 Pathogenesis of osteoporosis-related fractures, from Cooper and Melton, with modification [10]](https://figures.cochat.ai/paper-figures/ff3ff2f3f4b84a5bbd00a8cc79080d62/clinicians-guide-to-prevention-and-treatment-of-osteoporosis-figure-2.jpg)

Verification
Claims the paper makes
29 Valid · 18 Not valid · 68 Not checked · 17 Own results and interpretations
Some cited sources support this claim and some don’t — read each source’s verdict below.
In the paper
“Raloxifene is also indicated for the reduction in risk of invasive breast cancer in postmenopausal women with osteoporosis [83–86].”
§ Clinician’s Guide to Prevention and Treatment of Osteoporosis > Pharmacologic therapy > Estrogen agonist/antagonist (formerly known as SERMs): Raloxifene
What the sources say
- Not checked — no full text of the sourcecites [83] Cauley JA Norton L Lippman ME Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial. Multiple outcomes of raloxifene evaluation Breast Cancer Res Treat 2001 65 2 125 134 10.1023/A:1006478317173 11261828 source
- Disputedcites [84] Martino S Cauley JA Barrett-Connor E CORE Investigators Continuing outcomes relevant to Evista: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene J Natl Cancer Inst 2004 96 23 1751 1761 10.1093/jnci/djh319 15572757 sourceExperimental — accuracy not yet measured
The introduction (p. 1) says raloxifene was approved for preventing and treating postmenopausal osteoporosis, while tamoxifen was the only agent approved in the United States to reduce breast cancer incidence. Although the CORE results (p. 5) show reduced invasive breast cancer incidence with raloxifene, they do not support the claim that breast cancer risk reduction was an approved indication. (LLM, conf=0.88)
Checked by a reasoning model — may be wrong.
- Not checked — no full text of the sourcecites [85] Vogel VG Costantino JP Wickerham DL National Surgical Adjuvent Breast and Bowel Project (NSABP) Effects of tamoxifen vs. raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial JAMA 2006 295 23 2727 2741 10.1001/jama.295.23.joc60074 16754727 source
- Partly supportedcites [86] Barrett-Connor E Mosca L Collins P Raloxifene Use for The Heart (RUTH) Trial Investigators Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women N Engl J Med 2006 355 2 125 137 10.1056/NEJMoa062462 16837676 sourceExperimental — accuracy not yet measured
The Primary Outcomes (p. 5) report that raloxifene reduced invasive breast cancer in the RUTH trial, and the introductory text (p. 2) reports a similar finding from MORE, an osteoporosis-treatment trial. The paper does not state that breast-cancer risk reduction is an approved indication for postmenopausal women with osteoporosis; RUTH enrolled women with or at increased risk for coronary heart disease. (LLM, conf=0.84)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“Ibandronate reduces the incidence of vertebral fractures by about 50 % over 3 years, but reduction in risk of nonvertebral fracture with ibandronate has not been documented [50].”
§ Clinician’s Guide to Prevention and Treatment of Osteoporosis > Pharmacologic therapy > Bisphosphonates
What the sources say
- Disputedcites [50] Chesnut CH 3rd Skag A Christiansen C Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis J Bone Miner Res 2004 19 18 1241 1249 10.1359/JBMR.040325 15231010 sourceExperimental — accuracy not yet measured
The Clinical osteoporotic nonvertebral fractures section reports a statistically significant 69% reduction with daily ibandronate in women with a baseline femoral-neck BMD T score below −3.0. The Discussion cautions that this was a post hoc analysis and says there was no significant reduction in the overall population, but the unqualified claim that a reduction has not been documented overlooks the reported subgroup finding. Page numbers were not provided in the supplied passages. (LLM, conf=0.88)
Checked by a reasoning model — may be wrong.
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Disputed
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“A vertebral fracture is consistent with a diagnosis of osteoporosis, even in the absence of a bone density diagnosis, and is an indication for pharmacologic treatment with osteoporosis medication to reduce subsequent fracture risk [18, 21].”
§ Clinician’s Guide to Prevention and Treatment of Osteoporosis > Approach to the diagnosis and management of osteoporosis > Vertebral imaging
What the sources say
- Not checked — no full text of the sourcecites [18] Kanis JA Melton LJ 3rd Christiansen C Johnston CC Khaltaev N The diagnosis of osteoporosis J Bone Miner Res 1994 9 8 1137 1141 10.1002/jbmr.5650090802 7976495 source
- Supportedcites [21] Melton LJ Chrischilles EA Cooper C Lane AW Riggs BL How many women have osteoporosis? J Bone Miner Res 2005 20 5 886 892 10.1359/jbmr.2005.20.5.886 15931736 source
The conclusion (OSTEOPENIA, p. 6) distinguishes osteoporosis assessed by bone mineral measurements from established osteoporosis assessed by the occurrence of specific fractures. The introduction (p. 2) identifies vertebral fractures among the principal osteoporosis-related fractures, supporting the stated diagnosis without a bone-density diagnosis. (LLM, conf=0.91)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Help determine adequacy of patient compliance and persistence with osteoporosis therapy”
§ Clinician’s Guide to Prevention and Treatment of Osteoporosis > Approach to the diagnosis and management of osteoporosis > Biochemical markers of bone turnover
What the sources say
- Partly supportedcites [25] Burch J Rice S Yang H Neilson A Stirk L Francis R Holloway P Selby P Craig D Systematic review of the use of bone turnover markers for monitoring the response to osteoporosis treatment: the secondary prevention of fractures, and primary prevention of fractures in high-risk groups Health Technol Assess (Winchester, England) 2014 18 11 1 206 PMC4781229 24534414 sourceExperimental — accuracy not yet measured
The review’s “Compliance and persistence” section describes a model in which a bone turnover marker result could lead to a conclusion that compliance or treatment response was inadequate, but notes that the model did not include test-accuracy data. “Measures of adherence” says that a marker-identified non-response could reflect non-compliance or non-persistence, among several other causes. The source therefore supports markers as a possible clue, not as a way to determine the adequacy of both compliance and persistence. (LLM, conf=0.83)
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Predict magnitude of BMD increases with FDA-approved therapies”
§ Clinician’s Guide to Prevention and Treatment of Osteoporosis > Approach to the diagnosis and management of osteoporosis > Biochemical markers of bone turnover
What the sources say
- Partly supportedcites [25] Burch J Rice S Yang H Neilson A Stirk L Francis R Holloway P Selby P Craig D Systematic review of the use of bone turnover markers for monitoring the response to osteoporosis treatment: the secondary prevention of fractures, and primary prevention of fractures in high-risk groups Health Technol Assess (Winchester, England) 2014 18 11 1 206 PMC4781229 24534414 sourceExperimental — accuracy not yet measured
The Clinical Effectiveness and Cost-Effectiveness Evidence section reports correlations between changes in bone turnover markers and BMD, including a statistically significant but weak correlation during teriparatide treatment. It also says not all correlations were significant and cautions that their usefulness varies by population. The review does not establish that markers predict the magnitude of BMD increases across FDA-approved therapies generally. (LLM, conf=0.84)
plainstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
87 more claims · 25 with their cited sources checked
Create a free account to see all 132 claims and to verify the 18 references still open.
- Probably not a substantial claim. 26
- It may state two separate claims as one. 25
- The quote only partly states this claim. 1
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“this equated to a health care cost of $1088”
From Accuracy requirements for cost-effective suicide risk prediction among primary care patients in the US (2021) · cites this paper as [31]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Previous studies31,46,47,48 in emergency department patients have identified primarily benefits, including reductions in health care costs, medical retirement, and depressive symptoms.”
From Accuracy requirements for cost-effective suicide risk prediction among primary care patients in the US (2021) · cites this paper as [31]
Experimental — accuracy not yet measuredIn the citing paper
“yielding an uptake of 89.9%”
From Accuracy requirements for cost-effective suicide risk prediction among primary care patients in the US (2021) · cites this paper as [31]
In the citing paper
“this issue was addressed by instead performing a thorough cost accounting from 2 specific exemplar interventions.30,31”
From Accuracy requirements for cost-effective suicide risk prediction among primary care patients in the US (2021) · cites this paper as [31]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Clinician’s Guide to Prevention and Treatment of Osteoporosis > Approach to the diagnosis and management of osteoporosis > Diagnostic assessment
“Screening BMD and vertebral imaging recommendations for men are outlined in Table 8.”
§ Clinician’s Guide to Prevention and Treatment of Osteoporosis > Approach to the diagnosis and management of osteoporosis > Additional bone densitometry technologies
“Table: Table 8 Additional bone densitometry technologies”
Citations
Cites
Writing Group for the Women's Health Initiative Investigators (2002) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.288.3.321 · Cited by 15,889
Neer, R. M., Arnaud, C. D., Zanchetta, J. R., Prince, R., Gaich, G. A., Reginster, J.-Y., Hodsman, A. B., Eriksen, E. F., Ish-Shalom, S., Genant, H. K., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200105103441904 · Cited by 4,602
Incidence and Economic Burden of Osteoporosis-Related Fractures in the United States, 2005–2025
Burge, R., Dawson-Hughes, B., Solomon, D. H., Wong, J. B., King, A., & Tosteson, A. (2007) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.061113 · Cited by 4,026
Interventions for preventing falls in older people living in the community
Gillespie, L. D., Robertson, M. C., Gillespie, W. J., Sherrington, C., Gates, S., Clemson, L., & Lamb, S. E. (2012) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007146.pub3 · Cited by 3,966
Professor Kanis, J. A., Melton, L. J., Christiansen, C., Johnston, C. C., & Khaltaev, N. (1994) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.5650090802 · Cited by 3,849
Black, D. M., Cummings, S. R., Karpf, D. B., Cauley, J. A., Thompson, D. E., Nevitt, M. C., Bauer, D. C., Genant, H. K., Haskell, W. L., Marcus, R., et al. (1996) · The Lancet · doi:10.1016/s0140-6736(96)07088-2 · Cited by 3,846
Denosumab for Prevention of Fractures in Postmenopausal Women with Osteoporosis
Cummings, S. R., Martin, J. S., McClung, M. R., Siris, E. S., Eastell, R., Reid, I. R., Delmas, P., Zoog, H. B., Austin, M., Wang, A., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0809493 · Cited by 3,489 · cited 1×
“by about 40 %, and nonvertebral fractures by about 20 % over 3 years [56].”
BackgroundDecreased bioavailability of vitamin D in obesity
Wortsman, J., Matsuoka, L. Y., Chen, T. C., Lu, Z., & Holick, M. F. (2000) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/72.3.690 · Cited by 3,204 · cited 1×
“This regimen should be followed by maintenance therapy of 1500–2000 IU/day or whatever dose is needed to maintain the target blood level [37, 38].”
Background
Research works printed but not linked: 4
- Office of the Surgeon General (US) (2004) Bone health and osteoporosis: a report of the Surgeon General. Office of the Surgeon General (US), Rockville (MD). Available from: http://www.ncbi.nlm.nih.gov/books/NBK45513/. Accessed March 2014 20945569
- National Osteoporosis Foundation Physician’s guide to prevention and treatment of osteoporosis 2005 Washington, DC National Osteoporosis Foundation
- Institute of Medicine (US) Committee to review dietary reference intakes for vitamin D and calcium (2011). In: Ross AC, Taylor CL, Yaktine AL et al (eds) Dietary reference intakes for calcium and vitamin D. National Academies Press (US), Washington (DC). Available from: http://www.ncbi.nlm.nih.gov/books/NBK56070/. Accessed March 2014 21796828
- Cummings, SR, San Martin J, McClung MR et al (2009) FREEDOM Trial. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 361(8):756–765. (Erratum in: N Engl J Med. 2009;36(10):191) 19671655 · DOI · Paper page
Cited by
Items 3,901–4,000 of 4,108
El-Shafaey, S. W., El-Brashy, A. E.-W. S., Faheem, M. H., & Ibrahim, N. H. (2025) · Egyptian Rheumatology and Rehabilitation · doi:10.1186/s43166-025-00340-6
“This is applicable for post-menopausal women and males over 50 years, in accordance with WHO classification [25].”
Examination of osteosarcopenia in patients over 65 years old with hip fracture
Çakmak, Ş., Türkmen, İ., Kulalı, F., Sağlam, N., Ünnü, S. Ç., & Basat, S. (2025) · Northern Clinics of Istanbul · doi:10.14744/nci.2024.74340
Analay, P., Kara, M., Fırat, H. G., Çolak, A. F., Erdoğan, K., Aksakal, M. F., Yalçınkaya, B., Demirel, K., Sevinç, H., Küçüktoksöz, S., et al. (2025) · Journal of Clinical Densitometry · doi:10.1016/j.jocd.2025.101607
Impactul suplimentelor de calciu si vitamina D3 în profilaxia osteoporozei
GRAMĂ, I., NEAMȚU, I., MUNTEANU, M., et al. (2024) · Management in Health · doi:10.5233/z86fkb57
Shi, R., & Joshi, S. (2025) · Nutrition and health · doi:10.1007/978-3-031-87441-3_3
Shabir, M., Khan, M. A., Khan, M. Y., et al. (2025) · Cureus · doi:10.7759/cureus.87721
“This period also saw the approval and introduction of newer pharmacologic agents, including teriparatide, denosumab, and zoledronic acid, expanding treatment options for high-risk patients [20].”
Deshpande, J., & Singh, C. K. (2025) · BioMed Target Journal · doi:10.59786/bmtj.317
“Osteoporosis is a metabolic bone disease with a low bone mass and the microarchitectural deterioration of bone tissue that results in increased bone fragility and susceptibility to fractures 1 .”
Yoon, D., Lee, A. M., Yusuf, I., Putranto, T. A., Setiawan7, L., Hoyaranda, E., Bozdogan, S., Saputro, J. W., Cho, J. Y., Zhou, Q., et al. (2025) · Research Square · doi:10.21203/rs.3.rs-7061936/v1
Conversion total hip arthroplasty
Jin, J., & Lu, L. Y. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-10559-3.00038-x
Osteoporosis in liver cirrhosis
Lima, T. B., Santos, L. A. A., & Romeiro, F. G. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-21938-2.00019-9
Bedimo, R. (2025) · Oxford University Press eBooks · doi:10.1093/med/9780197812631.003.0033
Efficacy of Sigma Anti-bonding Molecule Calcium Carbonate on Bone Mineral DensityPreprint
Yoon, D., Lee, A., Yusuf, I., Putranto, T. A., Setiawan7, L., Hoyaranda, E., Bozdogan, S., Saputro, J. W., Cho, J. Y., Zhou, Q., et al. (2025) · Research Square · doi:10.21203/rs.3.rs-7061936/v2
Sheth, N. P., Krohn, K., Torkelson, J., Winzenrieth, R., Humbert, L., Pearman, L., Wang, Y., Boxberger, J. I., & Bostrom, M. P. (2025) · Bone Reports · doi:10.1016/j.bonr.2025.101858
“Osteoporosis significantly alters bone structure and reduces BMD, resulting in compromised strength at affected skeletal sites (Cosman et al., 2014).”
Zhang, H., & Li, K. (2025) · Pharmacognosy Magazine · doi:10.1177/09731296251360086
“…women postmenopause due to estrogen deficiency, leading to trabecular bone loss and increased risk of vertebral and distal radius fractures (Cosman et al., 2014), and type II—senile, occurring in individuals over 70, resulting from the aging of trabecular and cortical bones, often leading…”
Determinants of bone mineral density in Vietnamese adults: A multifactorial analysis
Thuy, B. T., Hung, N. T., Anh, N. T., et al. (2025) · Clinical Nutrition Open Science · doi:10.1016/j.nutos.2025.08.004
The Incidence of Premature Bone Demineralization in Breast Cancer Patients Under 65
Tibbetts, K. Q., Huang, K. A., Goltz, D., Levin, M., & Prakash, N. S. (2025) · Clinical Breast Cancer · doi:10.1016/j.clbc.2025.08.006 · Cited by 1
Vincentis, S. D., David, K., Antonio, L., & Rochira, V. (2025) · Springer eBooks · doi:10.1007/978-3-031-96376-6_22
Alzaben, N., Mokhtar, A. A., Altwijri, F., et al. (2025) · Cureus · doi:10.7759/cureus.90853
“Meta-analyses have likewise failed to provide definitive conclusions, and current clinical guidelines do not offer consistent recommendations regarding vitamin D supplementation in patients with a history of urolithiasis [11].”
Diaz, L. A., Els, V., Sari, N. W. P., Sitranata, M. J., Suteja, R. C., & Wati, K. D. K. (2025) · Academic and Clinical Pediatrics · doi:10.4103/acped.acped_13_25
Dong, W., Xiang, Z., Deng, Z., Ouyang, S., Liu, J., Li, H., Wei, Q. P., & Chen, X. (2025) · Research Square · doi:10.21203/rs.3.rs-7178660/v1
Exercise Behavior to Prevent Osteoporosis
Mohammadnabizadeh, S., & Mohammadi, M. (2025) · Nursing Research · doi:10.1097/nnr.0000000000000832
Advocating the Integration of Lifestyle Medicine in the Prevention and Management of Bone Diseases
Moudgil, K. (2025) · Annals of African Medicine · doi:10.4103/aam.aam_306_25
“[3,4] The use of validated instruments, such as food frequency questionnaires, physical activity scales, and fall risk assessment tools, ensures consistency and reproducibility of data.”
The Association of Bone-related Biomarkers With Incident Hip Fracture: A Nested Case-control Study
CROMER, S. J., Yu, E. W.-Y., Patorno, E., Curhan, G. C., & Paik, J. M. (2025) · Journal of the Endocrine Society · doi:10.1210/jendso/bvaf148
Metabolic and Endocrine Disorders
Gómez, M. P. A., Nikodinovska, V. V., Petrera, M. R., Fons, M. A. F., Phan, C. M., Sabir, N., & Bazzocchi, A. (2025) · Medical radiology · doi:10.1007/174_2025_617
Ružić, L., Rakovac, M., Bilić-Čurčić, I., Jakovac, D., & Berković, M. C. (2025) · Healthcare · doi:10.3390/healthcare13182328 · Cited by 1
“Additionally, their effectiveness may be restricted for athletes who cannot adhere to strict dosing regimens [1,57].”
InfluentialWeinreb, J. B., Carbone, J., Patel, H., et al. (2025) · Clinical Spine Surgery A Spine Publication · doi:10.1097/bsd.0000000000001921
Osteoporosis and Vertebral Compression Fracture
Kumar, V., & Basappa, R. K. (2025) · Springer eBooks · doi:10.1007/978-981-96-9091-6_10
Predictive Frameworks for Osteoporosis Identification: Harnessing GAMs and Rule-Based Models
Saranya, S., Christy, S., & Kumari, V. S. (2025) · Communications in computer and information science · doi:10.1007/978-3-032-02537-1_7
Postmenopausal Bone Loss in American Indian Women
Leyva, M. J., Aston, C. E., Stephens, L. D., Baker, M. Z., & Smith, B. J. (2025) · Journal of Women s Health · doi:10.1177/15409996251384811
Association between blood-derived biological aging and bone mineral density among US adults
Wu, L., Wang, J., Liu, X., Wang, X., & Yue, X. (2025) · BMC Musculoskeletal Disorders · doi:10.1186/s12891-025-09213-7
Low glenoid vault bone density is a risk factor for failure of proximal humerus fracture fixation
Czerwonka, N., Mastroianni, M. A., Hellwinkel, J. E., et al. (2025) · Journal of Shoulder and Elbow Surgery · doi:10.1016/j.jse.2025.09.008
Silva, M. N. D., Duarte, R. E. P., Torales, L. D. G., et al. (2025) · Salud Integral y Comunitaria · doi:10.62486/sic2026291
Jin, Y., Cho, M., & Lee, J. H. (2025) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.70895
“Pertaining to osteoporosis, understanding of the Receptor Activator of Nuclear Factor-κB Ligand (RANKL) signalling pathway and the role of sclerostin protein have enhanced comprehension of the disease and facilitated the development of therapeutic agents such as denosumab and romosozumab [1–3].”
Quan, K. Y., & Nantha, Y. S. (2025) · Springer eBooks · doi:10.1007/978-981-97-7640-5_50
Mousavi, A., Kargar, M., Fahimfar, N., Ostovar, A., Sari, A. A., & Daroudi, R. (2025) · Archives of Osteoporosis · doi:10.1007/s11657-025-01615-3
“Osteoporosis is characterized by low bone mineral density (BMD), microarchitectural deterioration of bone structure, compromised bone integrity, and an increased susceptibility to fracture [1].”
InfluentialPark, S.-R., Lee, B. H., Suk, K., Kim, N., Park, M., Park, S.-Y., Moon, S.-H., Kim, H., Shin, J., & Kwon, J.-W. (2025) · Clinics in Orthopedic Surgery · doi:10.4055/cios25064 · Cited by 1
“22,23) The observation that patients who received calcium or vitamin D supplements had a higher probability of undergoing a reprocedure for re-fractures than those treated with BPs or SERMs may initially seem counterintuitive.”
Botanical-Green Warriors: The Role of Medicinal Plants in Revolutionizing Cancer Treatment
Poonkuil, N. L. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-33761-1.00006-4
Bahouq, H., Bahouq, M., & Abdelmajid, S. (2025) · Reumatologia/Rheumatology · doi:10.5114/reum/203545 · Cited by 1
“Osteoporosis was defined using the World Health Organization (WHO) classification system as T-score ≤ –2.5 standard deviation (SD) of either the lumbar spine or femoral neck with the application of the Moroccan female normative data [9, 10].”
InfluentialSmart Diet Curation: Personalizing Nutrition for Multiple Health Conditions and Allergen Management
Reddy, B. O., Bhavani, C. S., Nyneisha, B., Kiranmai, P., & Lalitha, S. (2025) · Lecture notes in networks and systems · doi:10.1007/978-981-96-6537-2_21
Askarian, M., Baloochi, A., Vizeshfar, F., Mohammadizadeh, F., Mottahedi, M., & Abaszadeh, F. (2025) · BMC Public Health · doi:10.1186/s12889-025-25697-3 · Cited by 2
Knowledge mapping of osteoporotic fractures: a bibliometric analysis from 2014 to 2024
Cao, R., Wang, Z., Lu, S., Li, M., Zhao, X., Sun, H., Jiang, X., & Zha, Y. (2025) · Archives of Osteoporosis · doi:10.1007/s11657-025-01620-6
Examining the Psychosocial Dimensions of Stress in Osteoporosis: A Systematic Review
Şen, E. T. (2025) · Psikiyatride Guncel Yaklasimlar - Current Approaches in Psychiatry · doi:10.18863/pgy.1741254
Single nucleotide variants in VDR and GC genes associated with osteoporosis in Mexican women
Sevilla‐Montoya, R., Flores-Quijano, M. E., Tolentino‐Dolores, M. C., Martínez‐Meza, Y., Ortíz-Luna, G. F., Castañeda-de-la-Fuente, A., López-Rodriguez, L., Rodríguez-González, F. G., León‐Madero, L. F., Borboa-Olivares, H. J., et al. (2025) · Climacteric · doi:10.1080/13697137.2025.2584063
“…to severe complications, reduced quality of life, higher mortality rates and increased healthcare costs, particularly among postmenopausal women [5]. recent research has shed light on the genetic underpinnings of osteoporosis, particularly through the identification of single nucleotide…”
Zhao, X., Cai, C., Tang, C., Zhang, Z., Huang, X., & Chu, T. (2025) · Frontiers in Medicine · doi:10.3389/fmed.2025.1695044
Goost, H., Schepper, J. D., Rölfing, J. D., Aguado, H. J., Howe, J. G., & Huber, B. M. (2025) · Frontiers in Surgery · doi:10.3389/fsurg.2025.1661501 · Cited by 1
“Non-pharmacological interventions target modifiable risk factors such as diet modification, smoking cessation, excessive alcohol avoidance, and regular weight-and muscle-strengthening exercise (20–22).”
Medical Issues in Osteoporotic Hip Fractures
Whinney, C. M. (2012) · Springer eBooks · doi:10.1007/978-1-4614-2203-7_19
Yue, C., Ding, N., Xu, L.-L., Fu, Y.-Q., Guo, Y.-W., Yang, Y.-Y., Zhao, X.-M., & Sheng, Z. (2022) · Figshare · doi:10.6084/m9.figshare.19641871
Jiang, H., Deng, R., Deng, Y., Nie, M., Deng, Y.-X., Luo, H.-H., Yang, Y.-Y., Ni, N., Ran, C.-C., & Deng, Z.-L. (2021) · Figshare · doi:10.6084/m9.figshare.14608598
Pinheiro, M., Oliveira, J. S., Bauman, A. E., Fairhall, N., Kwok, W. S., & Sherrington, C. (2020) · Figshare · doi:10.6084/m9.figshare.13290653
Pinheiro, M., Oliveira, J. S., Bauman, A. E., Fairhall, N., Kwok, W. S., & Sherrington, C. (2020) · Figshare · doi:10.6084/m9.figshare.13290656
Jamshidi, A., Vojdanian, M., Soroush, M., et al. (2022) · Figshare · doi:10.6084/m9.figshare.20206430
Jiang, H., Deng, R., Deng, Y., Nie, M., Deng, Y.-X., Luo, H.-H., Yang, Y.-Y., Ni, N., Ran, C.-C., & Deng, Z.-L. (2021) · Figshare · doi:10.6084/m9.figshare.14608595
Li, Z., Wu, X., Li, H., Bi, C., Zhang, C., Sun, Y., & Yan, Z. (2024) · Figshare · doi:10.6084/m9.figshare.25495260
Pinheiro, M., Oliveira, J. S., Bauman, A. E., Fairhall, N., Kwok, W. S., & Sherrington, C. (2020) · Figshare · doi:10.6084/m9.figshare.13290659
Li, Z., Wu, X., Li, H., Bi, C., Zhang, C., Sun, Y., & Yan, Z. (2024) · Figshare · doi:10.6084/m9.figshare.25495206
Pinheiro, M., Oliveira, J. S., Bauman, A. E., Fairhall, N., Kwok, W. S., & Sherrington, C. (2020) · Figshare · doi:10.6084/m9.figshare.13290650
Jamshidi, A., Vojdanian, M., Soroush, M., et al. (2022) · Figshare · doi:10.6084/m9.figshare.20206433
Jamshidi, A., Vojdanian, M., Soroush, M., et al. (2022) · Figshare · doi:10.6084/m9.figshare.20206427
Lu, T., Forgetta, V., Keller‐Baruch, J., Nethander, M., Bennett, D., Forest, M., Bhatnagar, S., Walters, R. G., Lin, K., Chen, Z., et al. (2021) · Figshare · doi:10.6084/m9.figshare.13710811
Additional file 1 of Prediction of subsequent fragility fractures: application of machine learning
Zabihiyeganeh, M., Mirzaei, A., Tabrizian, P., et al. (2024) · Figshare · doi:10.6084/m9.figshare.25971688
Pinheiro, M., Oliveira, J. S., Bauman, A. E., Fairhall, N., Kwok, W. S., & Sherrington, C. (2020) · Figshare · doi:10.6084/m9.figshare.13290647
Jamshidi, A., Vojdanian, M., Soroush, M., et al. (2022) · Figshare · doi:10.6084/m9.figshare.20206436
Dou, J., Wang, J., & Zhang, Q. (2021) · Figshare · doi:10.6084/m9.figshare.15179368
Xu, B., Ma, G., Yang, L., Chen, X., Bian, B., Yang, B., Zhang, D., Qin, X., Zhu, L., Yin, H., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26027666
Xu, B., Ma, G., Yang, L., Chen, X., Bian, B., Yang, B., Zhang, D., Qin, X., Zhu, L., Yin, H., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26027594
Additional file 2 of Prediction of subsequent fragility fractures: application of machine learning
Zabihiyeganeh, M., Mirzaei, A., Tabrizian, P., et al. (2024) · Figshare · doi:10.6084/m9.figshare.25971769
Jiang, H., Deng, R., Deng, Y., Nie, M., Deng, Y.-X., Luo, H.-H., Yang, Y.-Y., Ni, N., Ran, C.-C., & Deng, Z.-L. (2021) · Figshare · doi:10.6084/m9.figshare.14608592
Phytochemicals and bone health: strengthening skeletal system and preventing osteoporosis
Sharma, D., Porasar, P., Dash, S., Das, P., Hazam, P. K., Dutta, K. N., Bora, N. S., & Sahariah, B. J. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-26494-8.00023-9
Chai, J. W. (2025) · Springer eBooks · doi:10.1007/978-981-95-1386-4_9 · Cited by 1
Vitamin D Supplementation in Breastfeeding Infants
Kaur, C., Sharma, A., Jangra, S., & Bhatia, R. (2025) · Springer eBooks · doi:10.1007/978-981-95-2994-0_6
Brazilian guidelines for the management of osteoporosis in diabetes mellitus
de Paula, F. A., Silva, B. C. C., d’Alva, C. B., Ohe, M. N., Madeira, M., Farias, L. B. E., de Holanda, N. C. P., Gomes, N. D., Filho, R. L. D. S., Lauria, M. W., et al. (2025) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-025-02063-2
Prieto, E. B., Febres, L., Ponce, C. B., Freile, C. E. N., Carrillo, C. P. P., Urresta, F. E., Vaca, P. S., Michilena, D., & Castro, A. X. B. (2025) · Techniques in Orthopaedics · doi:10.1097/bto.0000000000000725
Associations between walk ratio and osteoporosis and sarcopenia in community-dwelling older women
Kim, M., Park, S. H., & Lee, I. (2025) · Physical Activity and Nutrition · doi:10.20463/pan.2025.0032 · Cited by 1
Yu, C.-G., Shin, J.-W., Lee, B. H., Kim, H., Moon, S.-H., Park, S.-Y., & Kwon, J.-W. (2025) · Journal of Advanced Spine Surgery · doi:10.63858/jass.15.2.114
“3,4) Pharmacologic treatment for osteoporosis is broadly categorized into antiresorptive and anabolic agents.”
Reducing Hip Surgery Time by Automating X-ray Annotations Using Deep Learning
Bhole, V. Y., Amale, A., Kamble, A., et al. (2026) · Communications in computer and information science · doi:10.1007/978-3-032-12544-6_6
Yuksel, N., & Charrois, T. L. (2025) · Springer eBooks · doi:10.1007/978-3-032-10050-4_20
Bhushan, A., & Singh, R. K. (2025) · Springer eBooks · doi:10.1007/978-981-95-2676-5_72
A bibliometric analysis of acupuncture applied to primary osteoporosis
Yu, G., Song, H., Gao, Y., Chen, G., & Xu, Y. (2026) · Frontiers in Medicine · doi:10.3389/fmed.2025.1623239 · Cited by 1
Prevalence and Determinants of Osteoporosis Among Adults
Ahmed, A. S., Abdullah, A. K., & Sahm, S. F. (2025) · Academia Open · doi:10.21070/acopen.10.2025.12723
“According to Cosman et al. [9], increasing age, being female, postmenopausal status, hypogonadism or premature failure of ovaries, low body weight, parental hip fracture history, ethnicity (whites are more predisposed than blacks), previous clinical/ morphometric vertebral fracture, past fracture…”
Li, J., Li, S., Li, C., Chen, Z., & Ding, Y. (2026) · Drug Healthcare and Patient Safety · doi:10.2147/dhps.s543323
“This work shall address critical gaps in tirzepatide pharmacovigilance, informing clinical practice and regulatory policies to enhance patient safety amid therapeutic expansion.”
Sun, Y., Huang, J., Zhang, Z., Chen, Z., Li, Z., Wu, F., Wang, Z., Wu, T., Yi, G., Meng, F., et al. (2026) · International Journal of Endocrinology · doi:10.1155/ije/6619808
“Considering that the National Osteoporosis Foundation (NOF) recommends utilizing the lumbar spine BMD (LS-BMD) and the femoral neck BMD (FN-BMD) to defne OS, and due to the potential impact of sex, we made a sex-specifc analysis among LS-BMD and FN-BMD [19].”
Kim, J., Lee, B.-J., Bae, J.-B., Kim, S. B., Kim, D.-H., & Yoon, J.-Y. (2026) · Medicina · doi:10.3390/medicina62020299
Işıkcı, N. İ., & Demir, P. D. (2020) · DergiPark (Istanbul University)
Vrachnis, D. N., & Stratakis, C. A. (2026) · Elsevier eBooks · doi:10.1016/b978-0-323-96100-4.00005-3
Sawatwong, W., Niebur, G. L., Ramesh, P., Arora, D., Machireddy, M., Thimmapuram, J., Little, D., & Main, R. P. (2026) · JBMR Plus · doi:10.1093/jbmrpl/ziag016 · Cited by 1
Álvarez-Galovich, L., Arana, E., Blanco, J. F., et al. (2026) · Archives of Osteoporosis · doi:10.1007/s11657-026-01670-4
“…recommendations, the main areas of convergence and divergence between this national Delphi consensus and major international guidelines, including those from American Society for Bone and Mineral Research (ASBMR) [46] and National Osteoporosis Foundation (NOF) [47], are summarized in Table S9.”
Kamal, D. E., Fathi, N. A., Osman, A. O. B. S., Abdalmageed, A. M., & Galal, M. A. A. (2026) · Clinical Rheumatology · doi:10.1007/s10067-026-07966-7
“Primary osteoporosis includes involutional osteoporosis type I (postmenopausal osteoporosis, due to estrogen deficiency) and type II (senile osteoporosis) [2].”
Deal, C. L., Bostrom, M. P., Sheth, N. P., Humbert, L., Krohn, K., Wang, Y., & Boxberger, J. I. (2026) · Journal of Clinical Densitometry · doi:10.1016/j.jocd.2026.101686
Lv, P., Bai, J., Li, L., Zhang, C. X., Wei, S., & Chang, J. (2026) · Science Progress · doi:10.1177/00368504261426436
OSTEOPOROTIC FRACTURE RISK IN POSTMENOPAUSAL WOMEN: A SINGLE-CENTER, OBSERVATIONAL STUDY
Akbaş, E., & COŞKUN, S. (2026) · İnönü Üniversitesi Sağlık Hizmetleri Meslek Yüksek Okulu Dergisi · doi:10.33715/inonusaglik.1801662
Argynbaeva, A. A., Sakibaev, K. S., Eshiev, A., Исмаилов, А. А., Tashmatova, N. M., & Zhoroeva, A. (2025) · International Conference on Science Technology Engineering and Mathematics (ICONSTEM) · doi:10.1109/iconstem65670.2025.11374899
“Finally, this model allows customized healthcare data, the opportunity to identify the risks of osteoporosis early, and the evolution of inclusive medical AI use in bone health analysis in women [4].”
Chronic radiculopathy of occupational genealogy – current state of the problem
Lashko, O. M. (2024) · JOURNAL OF THE NATIONAL ACADEMY OF MEDICAL SCIENCES OF UKRAINE · doi:10.37621/jnamsu-2024-3-4-8
Metabolic bone abnormalities underlying nonunion in revision foot surgeries
Mursalov, A. K., Dzyuba, A. M., Shipilov, A. S., et al. (2026) · Genij Ortopedii · doi:10.18019/1028-4427-2026-32-1-57-64
Monjezi, D., Shojaie, B., & Salesi, M. (2026) · International Journal of Preventive Medicine · doi:10.4103/ijpvm.ijpvm_218_23
de Almeida, S. B., Lima, D. P., de Luna, J. R. G., Júnior, A. B. V., Filho, J. D. S. R., Alencar, Á. P., Rios-Júnior, W. O., de Oliveira, W., Lima, P. L. G. D. S. B., Nóbrega, P. R., et al. (2026) · Arquivos de Neuro-Psiquiatria · doi:10.1055/s-0046-1816034 · Cited by 1
Varatharajan, M., Abeysundara, S. P., Jayatilake, M. L., Abhayaratna, S., & Hewavithana, P. B. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1748490
Ukrajinská verzia FRAX pre posúdenie rizika zlomenín u žien s reumatoidnou artritídou
Povoroznyuk, V. V., Grygorieva, N. V., Ivanik, O., Bystrytska, M., Nataliia, D., Vasyl, P., Musiienko, A., & Zaverukha, N. V. (2020) · Clinical Osteology · doi:10.36290/clo.2020.017
Prevence sekundárních fraktur: multioborové konsenzuální stanovisko ke klinickým doporučením
Conley, R. B., Adib, G., Adler, R. A., Kristina, K. E., Ivy, A. M., Amenta, K. C., Robert, B. D., Brox, W. T., Emily, C. E., Chapman‐Novakofski, K., et al. (2020) · Clinical Osteology · doi:10.36290/clo.2020.002
Siggeirsdottir, L. A. H. N. C. V. G. K. M. J. K. J. H. G. S. (2020) · Clinical Osteology · doi:10.36290/clo.2020.023
Metadata
- Authors
- Cosman, F., de Beur, S. J., LeBoff, M. S., Lewiecki, E. M., Tanner, B., Randall, S., & Lindsay, R.
- Affiliations
- Helen Hayes Hospital (US)
- Brigham and Women's Hospital (US)
- New Mexico Clinical Research & Osteoporosis Center (US)
- Bone Health and Osteoporosis Foundation (US)
- Corresponding author
- Cosman, F.
- Venue
- Osteoporosis International
- Published
- 2014-08-15
- Volume
- 25
- Issue
- 10
- Pages
- 2359-2381
- ISSN
- 0937-941X (ISSN-L)
- 1433-2965
- PMC
- PMC4176573
- OpenAlex
- W2171709369
- Semantic Scholar
- 91c0d02cdbd4c5dd69ed206e6a0b2b94c9aa0830
- Cited by
- 4,149
- References
- 101
- Citations by year
- 2026: 141 · 2025: 226 · 2024: 267 · 2023: 292 · 2022: 351 · 2021: 415 · 2020: 458 · 2019: 336 · 2018: 311 · 2017: 304 · 2016: 285 · 2015: 246 · 2014: 141
- FWCI
- 242.08
- Type
- journal article
- Language
- en
- Update notices
- correction (2015-05-19)
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Osteoporosis International (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- PubMed Central (submittedVersion, cc-by-nc)
- Topics
- Health Sciences › Medicine › Orthopedics and Sports Medicine › Bone health and osteoporosis research
- Health Sciences › Medicine › Oncology › Bone health and treatments
- Health Sciences › Medicine › Surgery › Hip and Femur Fractures
- Keywords
- osteoporosis, osteoporosis prevention, osteoporosis treatment, bone health, osteoporosis drugs
- MeSH terms
- Aged, Calcium, Dietary, Diet, Female, Humans, Male, Middle Aged, Osteoporosis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-09-30, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-09-30 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.